雷帕霉素置于2,6-二甲基吡啶,盐酸,三氟甲磺酸酐体系中,用 甲醇,二氯甲烷,水 用作溶剂,化学反应 1.5H,反应生成依维莫司 参考文献: Process For The Synthesis Of Everolimus And Intermediates Thereof[fr] Procédé De Synthèse D'évérolimus Et D'Intermédiaires De Ce Dernier 标题: Process For The Synthesis Of Everolimus And Intermediates Thereof[fr] Procédé De Synthèse D'évérolimus Et D'Intermédiaires De Ce Dernier 摘要:这项发明涉及一种用于合成化学式(i)的依维莫司和其中间体的新工艺.
专利信息
专利号:US-11873305-B2 优先权日:2020-06-30 标题 :Processes for synthesis of substituted indole intermediates for the synthesis of serd compounds 发明人:ZHANG HAIMING; XU JIE; WUITSCHIK GEORG; ANGELAUD REMY; HEROLD SEBASTIAN; STUTZ ALFRED; BRUETSCH TOBIAS; BURKHARD JOHANNES 权利人:GENENTECH INC; HOFFMANN LA ROCHE 摘要:Provided herein are processes for the preparation of indolyl intermediates using Wenker Synthesis for the total synthesis of SERD compounds useful in the treatment of cancer.
专利号:US-9938297-B2 优先权日:2014-08-04 标 题:Process for the synthesis of everolimus and intermediates thereof 发明人:RAO DHARMARAJ RAMACHANDRA; MALHOTRA GEENA; PULLELA VENKATA SRINIVAS; ACHARYA VINOD PARAMESHWARAN 权利人:CIPLA LTD; CIPIA LTD 摘要:The present invention relates to a novel process for the synthesis of everolimus of formula (I): n nand intermediates thereof.
专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:US-9315483-B2 优先权日:2007-09-13 标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof 发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT 权利人:CONCERT PHARMACEUTICALS INC 摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.
专利号:US-2021220331-A1 优先权日:2016-05-03 标题:Inhibitors of ires-mediated protein synthesis 发明人:GERA JOSEPH F; LICHTENSTEIN ALAN; JUNG MICHAEL E; LEE JIHYE; HOLMES BRENT; BENAVIDES-SERRATO ANGELICA 权利人:UNIV CALIFORNIA; THE UNITED STATE GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS 摘要:This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
1: Hasskarl J. Everolimus. Recent Results Cancer Res. 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. 3: Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24. 4: Mousa OY, Keaveny AP. Everolimus: Longer-Term CERTITUDE. Liver Transpl. 2019 Dec;25(12):1745-1746. doi: 10.1002/lt.25659. 21(3):185-193. doi: 10.1007/s40272-019-00337-7. 205(6):12-13. doi: 10.1164/rccm.202103-0565IM. 30(1):3-12. doi: 10.1016/j.trre.2015.09.001. Epub 2015 Sep 18. 14(5):461-9. doi: 10.1016/s1499-3872(15)60419-2. 17(7):671-682. doi: 10.1080/17434440.2020.1784005. Epub 2020 Jun 30. 388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. 15(12):787-789. doi: 10.1158/1940-6207.CAPR-22-0419. 31(3):151-157. doi: 10.1016/j.trre.2017.02.007. Epub 2017 Feb 27. 114(6):312-313. doi: 10.17235/reed.2022.8902/2022. 41(5):568-574. doi: 10.1097/FTD.0000000000000628. 24(1):2206362. doi: 10.1080/15384047.2023.2206362.
合成参考文献
参考文献:10.1093/annonc/mdq029 摘要:Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010 Sep;21(9):1834–8. doi: 10.1093/annonc/mdq029. 参考文献:10.1007/s11892-011-0211-1 摘要:Bassi R, Fiorina P. Impact of islet transplantation on diabetes complications and quality of life. Curr Diab Rep. 2011 Oct;11(5):355–63. doi: 10.1007/s11892-011-0211-1. 参考文献:10.1007/s10549-011-1660-6 摘要:Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Luca G. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Research and Treatment. 2011 Jul 13;132(3):843–51. doi: 10.1007/s10549-011-1660-6. 参考文献:10.1007/s11912-011-0187-7 摘要:Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011 Oct;13(5):398–406. doi: 10.1007/s11912-011-0187-7.